Skip to main content
The Maple Markets

Cboe Canada · PFE.NE · ISIN CA7170651060

Pfizer Inc.

12.23 CAD

0.07(0.57%)down

Previous close · Sep 18, 11:36 ET

Data last updated: (1 d ago)· Delayed exchange data

Sign in to add to portfolio

Pfizer Inc. (PFE.NE) trades on Cboe Canada and operates in the Drug Manufacturers - General industry. Its market capitalisation is approximately 205.27B CAD. The company reports around 75,000 employees. Its ISIN is CA7170651060. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Checking today's session…

Key facts

Exchange

Cboe Canada

ISIN

CA7170651060

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

US

Market cap

204.77B CAD

Employees

75K

Previous close

12.30 CAD

Day range

12.18 – 12.27

52-week range

9.68 – 12.76

Volume

5.6K

50-day average

11.42 CAD

200-day average

11.19 CAD

Asset type

Equity

About Pfizer Inc.

Pfizer Inc. operates as a global biopharmaceutical enterprise, actively involved in the discovery, innovation, manufacturing, promotion, distribution, and sale of its pharmaceutical portfolio across the United States, Europe, and numerous international markets. The company’s comprehensive product range encompasses medicines and vaccines for a wide spectrum of therapeutic areas. These include treatments for cardiovascular and metabolic conditions, migraines, and women's health, exemplified by brands such as Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family. Pfizer also addresses infectious diseases with products like the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba, alongside its contributions to COVID-19 prevention and treatment, featuring Comirnaty and Paxlovid, and ongoing efforts in mRNA and antiviral technologies. Further offerings include biosimilars for chronic immune and inflammatory disorders, represented by Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo; and specialized medications for conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, found under brands like the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin. The company also supplies sterile injectable and anti-infective medications, including Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga, in addition to a substantial oncology and specialty pipeline featuring biologics, small molecules, immunotherapies, and biosimilars like Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi. Additionally, Pfizer engages in contract manufacturing services. Its clientele is diverse, spanning wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical offices, and integrated healthcare delivery systems. The company maintains significant collaboration agreements with partners such as Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE. Pfizer Inc. was established in 1849 and has its corporate headquarters situated in New York, New York.

Company website

Frequently asked

+
What is the PFE.NE share price today?
This page shows the latest available Pfizer Inc. (PFE.NE) price with its change against the prior close. Values are delayed or previous-close, not real-time.
+
Where is Pfizer Inc. listed?
Pfizer Inc. trades on Cboe Canada under the symbol PFE.NE, ISIN CA7170651060.
+
How large is Pfizer Inc.?
Its market capitalisation is approximately 205.27B CAD, based on the latest available price and share count from our data provider.

All Pfizer Inc. data comes from exchange and provider feeds for Cboe Canada and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.

We use necessary cookies to run the site and, only with your permission, analytics cookies to understand what readers use. Cookie policy